Peritonitis

1
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Biotest Pharmaceuticals
Biotest PharmaceuticalsGermany - Dreieich
1 program
1
Pentaglobin®/Standard of CarePhase 21 trial
Active Trials
NCT03334006RecruitingEst. Mar 2028
Pfizer
PfizerNEW YORK, NY
1 program
TygacilN/A1 trial
Active Trials
NCT00481962CompletedEst. Dec 2008

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
Biotest PharmaceuticalsPentaglobin®/Standard of Care
PfizerTygacil

Clinical Trials (2)

NCT03334006Biotest PharmaceuticalsPentaglobin®/Standard of Care

Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis

Start: Nov 2017Est. completion: Mar 2028
Phase 2Recruiting

Health Economic Assessment of Tygacil® in the Treatment of Secondary Peritonitis in Intensive Care Units (ICUs)

Start: Feb 2006Est. completion: Dec 2008
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials
2 companies competing in this space